Merck’s (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Merck’s (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.